DE69010330D1 - Fibroblasten-wachstumsfaktor-konjugate. - Google Patents

Fibroblasten-wachstumsfaktor-konjugate.

Info

Publication number
DE69010330D1
DE69010330D1 DE69010330T DE69010330T DE69010330D1 DE 69010330 D1 DE69010330 D1 DE 69010330D1 DE 69010330 T DE69010330 T DE 69010330T DE 69010330 T DE69010330 T DE 69010330T DE 69010330 D1 DE69010330 D1 DE 69010330D1
Authority
DE
Germany
Prior art keywords
growth factor
fibroblast growth
factor conjugates
conjugates
fibroblast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69010330T
Other languages
English (en)
Other versions
DE69010330T2 (de
Inventor
Douglas Lappi
Andrew Baird
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Application granted granted Critical
Publication of DE69010330D1 publication Critical patent/DE69010330D1/de
Publication of DE69010330T2 publication Critical patent/DE69010330T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE69010330T 1989-04-27 1990-04-26 Fibroblasten-wachstumsfaktor-konjugate. Expired - Fee Related DE69010330T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/344,109 US5191067A (en) 1989-04-27 1989-04-27 Fibroblast growth factor conjugates
PCT/US1990/002289 WO1990012597A1 (en) 1989-04-27 1990-04-26 Fibroblast growth factor conjugates

Publications (2)

Publication Number Publication Date
DE69010330D1 true DE69010330D1 (de) 1994-08-04
DE69010330T2 DE69010330T2 (de) 1994-10-20

Family

ID=23349097

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69010330T Expired - Fee Related DE69010330T2 (de) 1989-04-27 1990-04-26 Fibroblasten-wachstumsfaktor-konjugate.

Country Status (6)

Country Link
US (1) US5191067A (de)
EP (1) EP0470183B1 (de)
JP (1) JP2891306B2 (de)
CA (1) CA2053275C (de)
DE (1) DE69010330T2 (de)
WO (1) WO1990012597A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529932A (en) * 1988-01-28 1996-06-25 Pharmacia, S.P.A. Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
US5576288A (en) * 1989-04-27 1996-11-19 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5635384A (en) * 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
EP0552188B1 (de) * 1990-09-19 1998-03-11 The Salk Institute For Biological Studies Behandlung von tumorogenen pathophysiologischen zuständen durch verwendung von f4f-cytotoxinkonjugaten
US5478804A (en) * 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
AU1193492A (en) * 1991-01-03 1992-08-17 Salk Institute For Biological Studies, The Mitotoxin for treatment of vascular injury
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5916772A (en) * 1992-06-16 1999-06-29 Whittier Institute For Diabetes And Endocrinology Recombinant production of saporin-containing proteins
DE69435318D1 (de) * 1993-01-28 2010-12-09 Boston Scient Ltd Therapeutische inhibitoren der zellen der glatten gefässmuskulatur
WO1995007297A1 (en) * 1993-09-06 1995-03-16 Menarini Ricerche Sud S.P.A. Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
JPH09510352A (ja) * 1994-03-15 1997-10-21 プリズム ファーマシューティカルズ，インコーポレイティド 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
EP0923387B1 (de) * 1996-06-24 2001-09-26 Selective Genetics, Inc. Heparin-beschichtete medizinische geräte zum intravenösen gebrauch, die heparin-bindende wachstumfaktor-konjugate enthalten
US20050043234A1 (en) * 1996-10-16 2005-02-24 Deisher Theresa A. Novel FGF homologs
WO1998040508A1 (en) * 1997-03-14 1998-09-17 Selective Genetics, Inc. Adenoviral vectors with modified tropism
US7741435B2 (en) * 1997-07-09 2010-06-22 Advanced Targeting Systems, Inc. Substance P-saporin (SP-SAP) conjugates and methods of use thereof
US6063758A (en) * 1997-07-09 2000-05-16 Advanced Targeting Systems, Inc. Substance P-Saporin (SP-SAP) conjugates and methods of use thereof
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
DK1098664T3 (da) * 1998-07-22 2003-11-17 Osprey Pharmaceuticals Ltd Sammensætninger og deres anvendelser til at behandle sekundær vævsskade og andre inflammatoriske tilstande og forstyrrelser
AU2007201753B2 (en) * 1998-07-22 2008-11-27 Osprey Pharmaceuticals Usa, Inc. Nucleic acid molecules encoding cytotoxic conjugates that contain a chemokine receptor targeting agent
EP1225909A2 (de) * 1999-10-02 2002-07-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Fibroblasten-wachstumsfaktor 5 (fgf-5) ist ein tumorassoziertes t-zell-antigen
AU1804201A (en) * 1999-12-02 2001-06-12 Zymogenetics Inc. Methods for targeting cells that express fibroblast growth receptor-3 or-2
US7470665B2 (en) 1999-12-02 2008-12-30 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or -2
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
EP1497415B1 (de) 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Verfahren zum nachweis oder zur modulierung der wechselwirkung eines cytokinrezeptors mit seinem ligand
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
JP4754823B2 (ja) * 2002-10-07 2011-08-24 ザイモジェネティクス， インコーポレイテッド Ｆｇｆ１８の投与方法
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) * 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
EP1623715B1 (de) * 2004-07-13 2012-09-19 Charité - Universitätsmedizin Berlin Zusammensetzung, welche ein pharmakologisch aktives, an eine für eine Zielzelle spezifische Komponente gebundenes Mittel sowie ein Saponin enthält
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US7815926B2 (en) * 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
US8921109B2 (en) 2005-09-19 2014-12-30 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US8962556B2 (en) * 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
CA2717725A1 (en) * 2008-03-05 2009-09-11 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN165717B (de) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US5116753A (en) * 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets

Also Published As

Publication number Publication date
CA2053275A1 (en) 1990-10-28
CA2053275C (en) 1999-02-02
EP0470183A1 (de) 1992-02-12
DE69010330T2 (de) 1994-10-20
WO1990012597A1 (en) 1990-11-01
US5191067A (en) 1993-03-02
JP2891306B2 (ja) 1999-05-17
JPH04507093A (ja) 1992-12-10
EP0470183B1 (de) 1994-06-29

Similar Documents

Publication Publication Date Title
DE69010330T2 (de) Fibroblasten-wachstumsfaktor-konjugate.
DE69007311D1 (de) Konjugate.
DE69005219T2 (de) Prothese.
DE69020982D1 (de) Vulkanisierungsform.
NO892485D0 (no) Vanntett fottoey.
FI890803A (fi) Inmatningssystem foer braennluft i en aotervinningspanna.
NO903662L (no) Koplingsstykke.
FI922956A0 (fi) Interpolativ analog/digital- omvandlare.
FI890299A (fi) Form.
FI891419A0 (fi) Anordning i en gaengoeppningsanordning foer borrmaskineri.
FI890300A (fi) Form.
FI891719A (fi) Luftfoerdelningsroer i en pappersmaskin.
IT218230Z2 (it) Cassettiera.
FI891147A (fi) Vaermnings- och avfrostningssystem foer underredet i larvbandmaskiner.
FI892215A (fi) Foerraodsmodul i foerraodsutrymmen foer bostadsanvaendares personliga bruk.
FI890091A0 (fi) I bilens elkrets anslutningsbar uppvindningsanordning foer elledning.
FI890255A (fi) Lyftare foer innertaksskivor i byggnader.
FI891188A0 (fi) Foerpackning foer komponenter i en roerledning.
FI891189A0 (fi) Foerpackning foer komponenter i en roerledning.
FI894385A (fi) Aongpanneenhet i synnerhet foer vinterbruk.
FI890801A0 (fi) Faestmekanism foer kapsvaerd i en lastereharvester/faellhuvud.
FI892516A (fi) I koeksskaop anbringbart glidlaodsystem.
FI895476A (fi) Tillvaextunderlagskaerl foer anvaendning i temperaturgradientsinkubator.
FI894920A0 (fi) Stabiliseringsanordning foer dragarmarna i en traktor.
FI892694A (fi) Skyddspartier i en skyddsko.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee